There are a range of HER2-targeted therapies, including the monoclonal antibody trastuzumab, licensed for the treatment of breast and gastric cancers, and the trastuzumab–drug conjugate, T-DM1, licensed for the treatment of breast cancer [3, 4]. Here, ERBB2 is linked to gastric cancer.